Programs & products

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that safety data for two Phase I studies of lirilumab in combination with nivolumab or ipilimumab conducted by...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its seventh assessment of the EffiKIR study and...

Phase I study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas commenced in November 2015 and continues on track in EU and US centers Innate Pharma SA (the “Company” -...

Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the...

Preclinical data demonstrate enhanced anti-tumor efficacy by combining PD-1/PD-L1 pathway blockade and NKG2A checkpoint inhibitor; Resistance to PD-1 pathway blockers is associated with upregulation...

Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy; Strengthens Innate’s positioning in targeting the tumor microenvironment. Innate Pharma SA (the “Company” -...

First-in-class anti-MICA/B therapeutic antibody; New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation; IND-enabling studies starting in 2016...

Five posters presented by Innate Pharma and collaborators; New data further supporting the rationale of four of Innate’s clinical and preclinical programs; New checkpoint inhibitor program targeting...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its sixth assessment of the EffiKIR study and...